ASN: Atrasentan Significantly and Clinically Meaningfully Cuts Proteinuria
By Lori Solomon HealthDay Reporter
WEDNESDAY, Oct. 30, 2024 -- Atrasentan is associated with a significant and clinically meaningful reduction in proteinuria compared with placebo in patients with immunoglobulin A (IgA) nephropathy, according to a study published online Oct. 25 in the New England Journal of Medicine to coincide with Kidney Week, the annual meeting of the American Society of Nephrology, held from Oct. 23 to 27 in San Diego.
Hiddo J. L. Heerspink, Ph.D., from the University of Groningen in the Netherlands, and colleagues assessed the efficacy and safety of the selective endothelin type A receptor antagonist atrasentan in reducing proteinuria in patients with IgA nephropathy. The analysis included 270 patients randomly assigned to either atrasentan (0.75 mg per day) or placebo for 132 weeks.
The researchers found that the geometric mean percentage change in the urinary protein-to-creatinine ratio relative to baseline was significantly greater with atrasentan (−38.1 percent) than with placebo (−3.1 percent), with a geometric mean between-group difference of −36.1 percentage points. The percentage of patients with adverse events was similar between the two groups. Fluid retention occurred in 11.2 percent in the atrasentan group and in 8.2 percent in the placebo group but did not lead to discontinuation of the trial regimen. There were no cases of cardiac failure or severe edema reported.
"In this prespecified interim analysis, atrasentan resulted in a significant and clinically meaningful reduction in proteinuria as compared with placebo in patients with IgA nephropathy," the authors write.
The study was funded by Novartis, the developer of atrasentan.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-10-31 06:00
Read more
- AAP: Low Vitamin D Linked to Slower Fracture Healing in Pediatric Patients
- UCB Receives U.S. FDA Approval for 320 mg Single-Injection Device Presentations of Bimzelx (bimekizumab-bkzx)
- Referral to Hepatology Low With Excessive Alcohol Use, High FIB-4
- GLP-1 Weight-Loss Meds, Wegovy, Zepbound, Won't Raise Teens' Suicide Risk, May Even Lower It
- Ozempic Curbs Kidney Disease in Obese People Without Diabetes
- Flu-Linked Hospitalization Rates Vary Across Seasons, Highest in Adults 65+
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions